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Summary
Pax5 is indispensable for the commitment of early lym-
phoid progenitors to theBcell lineage aswell as for the
development of B cells. To better understand the func-
tional importance of Pax5 at the later stages of B cell
differentiation, we established a Pax5-deficient DT40
B cell line. The Pax5 -/- cells exhibited slower growth,
decreased surface IgM expression, and total loss of
B cell receptor signaling. Moreover, the expression
of the plasma cell-characteristic transcription factors
Blimp-1 and XBP-1 were significantly upregulated and
the expression of Bcl-6 diminished in the Pax5 -/- cells,
and thisalterationwasnormalizedby restoredPax5ex-
pression. The Pax5-deficient cells further manifested
substantially elevated secretion of IgM into the super-
natant, another characteristic of plasma cells. These
results indicate that downregulation of Pax5 function
promotes the plasma cell differentiation of B cells.
Introduction
The commitment of progenitor cells to the B cell lineage
is critically controlled by the transcription factor Pax5
(also known as the B cell-specific activator protein,
BSAP). In Pax5-deficient mice, B cell development is ar-
rested at an early pro-B cell stage in the bone marrow
(Urba´nek et al., 1994), and pro-B cells of Pax5-/- mice
show characteristics of uncommitted progenitors by
retaining a broad lympho-myeloid developmental poten-
tial (Nutt et al., 1999; Rolink et al., 1999; Schaniel et al.,
2002). This multilineage potential is suppressed by res-
toration of Pax5 expression, which also rescues the
pro-B cell arrest of Pax5-/- mice (Nutt et al., 1999).
Thus, Pax5 can be considered as a key regulator of the
B cell lineage commitment and early B cell development.
Pax5 facilitates the commitment of progenitor cells
by activating B cell-specific genes and simultaneously
suppressing expression of genes that are inappropriate
for the B cell development (reviewed in Busslinger,
*Correspondence: kalle-pekka.nera@utu.fi2004). Pax5 promotes B cell differentiation by activating
the transcription of Iga (CD79a, mb-1) (Fitzsimmons
et al., 1996; Nutt et al., 1998), BLNK (SLP-65) (Schebesta
et al., 2002), and CD19 (Kozmik et al., 1992; Nutt et al.,
1998). These three proteins function in the pre-BCR-sig-
naling pathway, which constitutes a critical develop-
mental checkpoint in the B cell differentiation. Moreover,
Pax5 binds to the VpreB and l5 promoters (Tian et al.,
1997) and participates in the assembly of pre-BCR com-
plex itself, as it also activates expression of themchain by
controlling the second VH-DJH recombination step of the
IgH gene (Nutt et al., 1997; Hesslein et al., 2003). Ectopic
Pax5 expression in T lymphocytes induces distal VH-DJH
recombination and locus contraction of IgH (Fuxa et al.,
2004; Hsu et al., 2004). Furthermore, evidence that
Pax5 is essential for sterile k transcription during Igk
chain gene rearrangement (Tian et al., 1997; Sato et al.,
2004) indicates a role for Pax5 also in the regulation of
IgL chain rearrangement.
Pax5 is exclusively expressed in the B lineage of lym-
phoid differentiation from the pro-B to the mature B
cell stage (Barberis et al., 1990; Adams et al., 1992), but
not in terminally differentiated plasma cells (Barberis
et al., 1990). It is believed that B lymphocyte-induced
maturation protein 1 (Blimp-1)-dependent repression of
Pax5 is required for the plasma cell development (Lin
et al., 2002), which is further supported by the fact that
enforced Pax5 expression appears to prevent B cell
activation-induced plasmacytic differentiation (Usui
et al., 1997; Morrison et al., 1998; Lin et al., 2002). Condi-
tional inactivation of Pax5 leads to the total loss of iden-
tity and function of mature mouse B cells (Horcher et al.,
2001), indicating that Pax5 is required to maintain B cell
identity in late B cell development. Moreover, Pax5 binds
to the activation-induced cytidine deaminase (AID) pro-
moter, and enforced expression of Pax5 can induce
AID expression in pro-B cell lines (Gonda et al., 2003),
suggesting that Pax5 may also have an active role in
the regulation of AID expression. AID is indispensable
for somatic hypermutation (SHM), class switch recom-
bination (CSR), and immunoglobulin gene conversion
(Muramatsu et al., 2000; Arakawa et al., 2002), which
are central events of B cell development and activation
that diversify rearranged Ig genes to produce differ-
ent isotypes of high-affinity antibodies. Hence, Pax5
appears to have an important function also in the late
B cell development and activation.
Due to the pro-B cell arrest of Pax5-/- mice (Urba´nek
et al., 1994), the role of Pax5 in later stages of B lineage
development is difficult to study in murine system. To
gain insight, we established a novel Pax5-deficient
DT40 B cell line. The chicken B cell line DT40 is surface
IgM positive, but continues Ig gene conversion and
seems to be arrested at the bursal B cell stage (Buer-
stedde et al., 1990). We show here that Pax5-/- DT40 cells
exhibited retarded growth, decreased sIgM expression,
and total loss of BCR signaling characterized by down-
regulation of Igb, BLNK, and Lyn. More importantly, the
expression of plasmacytic transcription factors Blimp-1
and X-box binding protein 1 (XBP-1) were significantly
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tant decrease of Bcl-6 transcription. Pax5-/- cells further
manifested their plasmacytic phenotype by showing
substantially elevated secretion of IgM into the superna-
tant. The altered expression levels of Blimp-1, XBP-1,
and Bcl-6 were normalized by reintroduction of Pax5 ex-
pression. Our results provide evidence that Pax5 not
only maintains the identity of B cells but also inhibits
plasma cell differentiation.
Results
Disruption of the Pax5 Gene in DT40 Cells
We disrupted the Pax5 gene of DT40 cells by using
different targeting constructs for both of the alleles
(Figure 1A). The DNA binding motif critical for the func-
tion of Pax5 is encoded by base pairs 48–429 of the
coding sequence. Targeted integration of the pax5-neo
vector into the third exon of the Pax5 gene leads to the
deletion of coding base pairs 192–405 and the deletion
of about 1.5 kb from the third intron sequence. Attempts
to generate Pax5-/- cells by transfection of a bsr con-
struct similar to pax5-neo were unsuccessful, since this
construct integrated preferentially into the already tar-
geted allele and not into the remaining wild-type allele.
Therefore, a different pax5-bsr vector was constructed
(Figure 1A) whose integration into the third exon of the
second Pax5 allele resulted in the deletion of the coding
base pairs 192–306.
The targeted integration of the pax5-neo and pax5-bsr
constructs was verified by genomic PCR by means of
the Pax5-specific primer 2f with the selection marker-
specific primers (neo-f and bsr-f) and a subsequent
Southern blot (Figure 1B) with the Pax5-specific probe
p2 (Figure 1A). Analysis by polymerase chain reaction
with reverse transcription confirmed that the Pax5-/-
DT40 cells did not express full-length Pax5 transcripts
(Figure 1C). The absence of Pax5 was further verified
by the Pax5-specific antibodies. Moreover, we restored
the expression of Pax5 in Pax5-/- cells (Pax5-/-/Pax5
cells; Figure 1D) in order to study the complementation
of the phenotype.
Impaired Cellular Growth and Loss of Functional
B Cell Identity in the Absence of Pax5
The Pax5-deficient cells exhibited a slower growth rate
and were not able to achieve cell densities comparable
to the wild-type cells. Reintroduction of the Pax5 did not
fully restore the cellular growth. However, the growth of
the Pax5-/-/Pax5 cells was more comparable to that of
wild-type cells (Figure 2A), indicating that the fast prolifer-
ation and highcelldensitycharacteristicofwild-typeDT40
is dependent on Pax5. Surface expression of IgM was
clearly decreased, but not entirely abolished, in Pax5-de-
ficient cells. Restoration of Pax5 expression reconstituted
sIgM expression (Figure 2B), demonstrating a role for
Pax5 in the maintenance of normal BCR expression level
at the cell surface. In contrast, cell surface expression of
chB6, which is expressed in all avian B cells (Pink and
Rijnbeek, 1983), was unaltered in the absence of Pax5.
To investigate the role of Pax5 in BCR signaling, we
analyzed the calcium influx induced by sIgM crosslink-
ing. In the absence of Pax5, calcium influx induced by
BCR signaling was totally abolished (Figure 3A). Tofurther study the nature of the BCR-signaling defect,
we analyzed the phosphorylation of cytoplasmic signal-
ing molecules after BCR crosslinking or stimulation of
the cells with H2O2, which bypasses the antigen-driven
BCR signal. Phosphorylation induced by BCR crosslink-
ing was totally abolished in the Pax5-/- cells (Figure 3B),
but H2O2-induced phosphorylation still occurred. How-
ever, the pattern of phosphorylated proteins in the Pax5-
deficient cells was quite different compared to the wild-
type cells (Figure 3C). These findings indicate that there
is a major defect or even total block in early steps of BCR
signaling, which can be overcome in part if the initial
events of BCR signaling are bypassed with H2O2.
To define the BCR-signaling defect in the Pax5-defi-
cient cells more precisely, we compared the gene-
expression profiles of the Pax5-/- and wild-type DT40
cells by using a novel BursaEST array (ArrayExpress ac-
cession: A-MEXP-155). The array contains about 15,000
probes in duplicate that are derived from the bursal
B cells. Array analysis (ArrayExpress accession: E-
MEXP-270) revealed downregulation of Igb, BLNK, and
Lyn related to the wild-type levels (Table 1). The results
Figure 1. Gene Targeting of the Pax5 Locus in DT40 B Cells
(A) Schematic presentation of the targeting constructsPax5-neo and
Pax5-bsr containing neomycin and blasticidin resistance markers,
respectively. Coding exons 2–4 of Pax5 gene are numbered.
(B) Targeted integration in thePax5 locus was monitored by genomic
PCR reactions in which Pax5-specific primer 2f was paired with se-
lection marker-specific primers neo-f or bsr-f. The obtained genomic
PCR products were hybridized with the Pax5-specific primer p2 to
verify the identity of the amplified fragments.
(C) Southern blot of RT-PCR to analyze Pax5 expression of wild-type
(wt), Pax5+/-, and Pax5-/- cells.
(D) Immunoprecipitation (IP) of Pax5 followed by immunoblot (IB)
with Pax5-specific antibody.
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time quantitative PCR (Q-PCR), which showed that the
expression levels of Igb, BLNK, and Lyn were decreased
in the Pax5-deficient cells to 6%, 39%, and 16% of wild-
type levels, respectively. Expression of Igb, BLNK, and
Lyn were restored to wild-type levels in the Pax5-/-/
Pax5 back transfectant cells. Moreover, further quanti-
tative PCR analysis showed that the expression level
of Btk in the Pax5-/- cells was about 50% of the expres-
sion level in the wild-type cells (Table 1). Thus, Pax5-de-
ficient DT40 cells have lost their functional B cell identity,
as they express only low levels of surface IgM and fail to
respond to sIgM crosslinking, and the expression levels
of several critical components of the BCR-signaling ma-
chinery are downregulated.
Loss of Pax5 Induces IgM Secretion
and Plasmacytic Differentiation
Interestingly, the array analysis and quantitative PCR re-
vealed that the expression of VpreB3 was significantly
Figure 2. Cell Growth and Surface Expression in the Absence of
Pax5
(A) Time versus cell density growth curves of wild-type (wt), Pax5-/-,
and Pax5-/-/Pax5 cells, showing slower growth in DT40 Pax5
mutants. Error bars indicate mean SD of independent experiments
(n = 3).
(B) Flow cytometric analysis of surface immunoglobulin (sIgM) and
chB6 expression as indicated by logarithmic fluorescence intensity
versus relative cell number.downregulated with a concomitant increase in Ig l light
chain (IgL) mRNA expression in the Pax5-/- DT40 cells
(Table 1). The downregulation of VpreB3 expression
was indeed due to the loss of Pax5, as Pax5 reexpres-
sion in the Pax5-/-/Pax5 cells restored VpreB3 expres-
sion. VpreB3 is expressed at high level from the pro-B
to the immature B cell stage, where it binds to free IgL
chains, preventing their maturation and secretion (Rosnet
et al., 2004). Hence, the diminished VpreB3 expression
could imply increased secretory activity in the Pax5-/-
cells.
Pax5 is also known to repress the expression of XBP-1
(Reimold et al., 1996), IgH (Singh and Birshtein, 1993),
and J chain (Rinkenberger et al., 1996; Wallin et al.,
1998, 1999), which are involved in the Ig secretion. Con-
sidering this and given the diminished VpreB3 expres-
sion in the absence of Pax5 (Table 1), we next analyzed
the IgM secretion and the expression levels of transcrip-
tion factors XBP-1, Blimp-1, and Bcl-6, which are differ-
entially expressed during the plasma cell differentiation.
Figure 3. BCR Signaling in Pax5-Deficient Cells
(A) Comparison of calcium mobilization in wild-type (wt) and Pax5-/-
cells following the BCR crosslinking, at the time indicated by the
arrow.
(B) Phosphorylation of cytoplasmic signaling molecules following
BCR crosslinking. Phosphotyrosine immunoblots of whole-cell ly-
sates were prepared before BCR engagement and 1, 3, or 10 minutes
after BCR engagement.
(C) Phosphorylation of cytoplasmic signaling molecules following
stimulation with H2O2.
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the plasmacytic transcription factors XBP-1 and Blimp-1
were clearly upregulated in the absence of Pax5
(Figure 4A). Restoration of Pax5 expression in the
Pax5-/-/Pax5 cells normalized Blimp-1 transcription to
the level observed in the wild-type cells. The expression
of XBP-1 was decreased significantly in thePax5-/-/Pax5
cells compared to the Pax5-deficient cells, but it re-
mained slightly upregulated compared to the wild-type
cells. These findings suggest that Pax5 is needed to sup-
press both XBP-1 and Blimp-1, which are essential for
the plasmacytic differentiation. The number of Bcl-6
transcripts diminished in the Pax5-/- cells compared to
the wild-type cells (Figure 4A). In the Pax5-/-/Pax5 cells,
in which Pax5 is overexpressed (Figure 1D), Bcl-6 ex-
pression was restored and even upregulated compared
to the wild-type cells (Figure 4A), indicating the involve-
ment of Pax5 in the maintenance of Bcl-6 transcripts.
Collectively, the upregulation of XBP-1 and Blimp-1
with diminished Bcl-6 expression are indications for
early plasmacytic differentiation of Pax5-/- cells.
XBP-1 promotes Ig secretion by coordinating various
cellular changes that are needed for the secretory phe-
notype of plasma cells (Shaffer et al., 2004). Given that
XBP-1 mRNA is spliced by IRE1 in response to stress
in the endoplasmic reticulum (ER) and that only the
spliced form of XBP-1 can activate the unfolded protein
response (UPR) and secretion (Yoshida et al., 2001), we
next analyzed the XBP-1 splice variants. The wild-type
cells expressed both isoforms of XBP-1 at low level,
whereas in thePax5-/- andPax5-/-/Pax5 cells, the spliced
form of XBP-1 was predominantly expressed at the
mRNA level (Figure 4B), indicating that XBP-1 is spliced
after the Pax5 deficiency. However, in contrast to XBP-1
expression, apparently Pax5 does not control XBP-1
splicing, as it remains unaltered regardless of restored
Pax5 expression.
We next analyzed the IgM secretion of Pax5-deficient
DT40 cells. The relative number of transcripts coding the
secretory form of IgM heavy chain (mS) was increased
more than 10-fold in the Pax5-/- cells compared to the
wild-type cells (Figure 4C). In contrast, the expression
level of the membrane form of IgM heavy chain (mM)
was not altered. Reintroduction of Pax5 expression de-
Table 1. Differentially Expressed Genes in Wild-Type, Pax5-/-,
and Pax5-/-/Pax5 Cells
Pax5-/- Pax5-/-/Pax5
Differentially Expressed Genes Array Q-PCR Q-PCR
CD79b/Igb 0.4 0.06 1.07
BLNK 0.53 0.39 1.38
Lyn 0.33 0.16 0.94
Btk 0.5 n.d.
VpreB3 0.18 0.03 0.89
IgL 2.55 n.d.
HSP70 5.8 9.7 n.d.
ITM2A 0.53 0.38 n.d.
HMG-17 0.45 0.45 n.d.
Caspase 3 0.53 0.43 n.d.
The expression levels obtained by BursaEST array analysis or by
quantitative PCR (Q-PCR) are given as values compared to the ex-
pression level in wild-type cells, which is given the value 1. The re-
sults are expressed as fold differences. n.d., not done.creased the relative number of mS transcripts in the
Pax5-/-/Pax5 cells, although not back to the level of
wild-type cells. The ELISPOT analysis of thePax5-/- cells
indicated elevated frequency of cells secreting IgM,
which was decreased by the restored Pax5 expression
(Figure 4D). Moreover, the pulse chase metabolic label-
ling with L-[35S]methionine and L-[35S]cysteine followed
by IgM immunoprecipitation clearly showed that more
IgM was secreted into the supernatant of thePax5-/- cells
compared to the wild-type cells. The IgM secretion was
reduced, although not to the level of wild-type cells, by
reintroduction of Pax5 expression (Figure 4E), which is
in line with the observation that XBP-1 is spliced in the
Pax5-/-/Pax5 cells (Figure 4B).
Pax5 Is Needed to Maintain an Adequate Level
of Bcl-6
Considering that Bcl-6 is needed to suppress the
Blimp-1 expression (Reljic et al., 2000; Shaffer et al.,
2000; Tunyaplin et al., 2004) while the Blimp-1 expres-
sion contributes to the inhibition of Bcl-6 expression
(Shaffer et al., 2002), we next addressed the question
of whether downregulation of Bcl-6 or upregulation of
Blimp-1 would constitute the primary effect in the ab-
sence of Pax5.
To test whether Bcl-6 is sufficient to suppress the
Blimp-1 expression in the absence of Pax5, we trans-
fected Bcl-6 into the Pax5-/- DT40 cells. In the indepen-
dent transfectant clones (Bc1, Bc2, and Bc3), Blimp-1
expression was downregulated close to the level ob-
served in the wild-type cells (Figure 5A), thus indicating
that Pax5 is not required for the inhibition of Blimp-1.
However, enforced Bcl-6 expression had no effect on
the upregulated XBP-1 expression of the Pax5-/- cells
(data not shown), verifying that Pax5, not Bcl-6, is re-
quired to suppress XBP-1. Furthermore, we wanted to
test whether the downregulation of Pax5 is necessary
for the suppression of Bcl-6 by Blimp-1. To study this,
we transfected Blimp-1 into thePax5-/-/Pax5 cells having
an inactive endogenous Pax5 locus and ectopically en-
forced Pax5 expression. In the transfectant cells (Px/
B1), Blimp-1 was able to downregulate Bcl-6 expression
regardless of the ectopic Pax5 expression (Figure 5B),
indicating that Blimp-1 does not inhibit the Bcl-6 expres-
sion via suppression of Pax5 expression. However, en-
forced Blimp-1 expression did not alter the downregula-
tion of XBP-1 expression in the Px/B1 cells (data not
shown), suggesting that Blimp-1 upregulates XBP-1
expression via suppression of Pax5 expression.
In summary, these results provide evidence that Pax5
is not needed to inhibit Blimp-1 expression, suggesting
that a drop in the level of Bcl-6 is likely to cause the
Blimp-1 induction in the absence of Pax5, and indicating
that Pax5 is needed for the maintenance of Bcl-6 rather
than for the inhibition of Blimp-1.
Pax5 Regulates the Expression of AID
and the Transcription Factors Aiolos
and EBF in DT40 Cells
Given that the putative regulatory region of AID contains
binding sites for Pax5 and that AID transcription can be
induced by enforced Pax5 expression in pro-B cell lines
(Gonda et al., 2003), we next examined the transcription
of AID in the Pax5-/- DT40 cells. The relative number of
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287Figure 4. Analysis of Pax5-Deficient DT40
Cells for Signs of Plasmacytic Differentiation
(A) Analysis of XBP-1, Blimp-1, and Bcl-6 ex-
pression in wild-type (wt), Pax5-/-, and
Pax5-/-/Pax5 cells by quantitative PCR.
Mean SD of four independent experiments
(n = 4) is indicated by error bars. The relative
number of transcripts in the Pax5-/- and
Pax5-/-/Pax5 cells is shown in comparison
to the level of transcripts in the wild-type
cells, which is given the value 100 and indi-
cated by a dashed line.
(B) RT-PCR analysis of XBP-1 splice variants
in wild-type (wt), Pax5-/-, and Pax5-/-/Pax5
cells.
(C) Quantitative PCR analysis of the secretory
(mS) and the membrane (mM) form of m heavy
chain transcripts. Error bars indicate mean
SD of independent experiments (n = 4). The
relative number of transcripts in the Pax5-/-
and Pax5-/-/Pax5 cells is shown as a compar-
ison to the level of transcripts in the wild-type
(wt) cells, which is given the value 100 and in-
dicated by a dashed line.
(D) Enzyme-linked immunospot (ELISPOT)
assay of wild-type (wt), Pax5-/-, and Pax5-/-/
Pax5 cells. Error bars indicate mean SD of
independent experiments (n = 3) for each
sample.
(E) Pulse-chase metabolic labelling followed
by IgM immunoprecipitation for wild-type
(wt), Pax5-/-, and Pax5-/-/Pax5 cells. Secreted
IgM was immunoprecipitated from the cell
culture supernatant after 0, 30 min, 1 hr, 2
hr, and 4 hr chase times. Components of the
secreted IgM (Igm and Igl) are indicated
with arrows.AID transcripts in the Pax5-deficient cells was dimin-
ished by 98% compared to the wild-type cells
(Figure 5C). However, in the Pax5-/-/Pax5 cells overex-
pressing the Pax5 (Figure 1D), the relative number of
AID transcripts was more than 4-fold greater than inthe wild-type cells (Figure 5C), showing that Pax5 posi-
tively regulates the AID expression in B cells. Further-
more, cells from clone Bc2 expressing Bcl-6 in the
absence of Pax5 had abolished AID expression, in con-
trast to the Px/B1 cells expressing both Blimp-1 and
Immunity
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and Blimp-1 Transfectants and Influence of
Pax5 on the Expression of AID, Aiolos, and
EBF
(A) Comparison of Bcl-6 and Blimp-1 tran-
scripts in wild-type (wt), Pax5-/-, and Bcl-6
transfectant Pax5-deficient cells (clones
Bc1, Bc2, and Bc3) by quantitative PCR.
The mean SD of three independent experi-
ments (n = 3) is indicated by error bars.
(B) Comparison of Blimp-1 and Bcl-6 tran-
scripts in wild-type (wt), Pax5-/-, Blimp-1
transfectant wild-type (WT/B1), and Blimp-1
transfectant Pax5-/-/Pax5 (Px/B1) cells by
quantitative PCR. The mean SD of three
independent experiments (n = 3) is indicated
by error bars.
(C) Quantitative PCR analysis of the AID tran-
scripts in wild-type (wt), Pax5-/-, and Pax5-/-/
Pax5 cells, as well as in the clone Bc2
(expressing Bcl-6 in the absence of Pax5)
and in the Px/B1 cells (expressing both
Pax5 and Blimp-1 ectopically). The mean SD
of four independent experiments (n = 4) is
indicated by error bars.
(D) Analysis of the Aiolos and EBF expression
in wild-type (wt), Pax5-/-, and Pax5-/-/Pax5
cells by quantitative PCR. The mean SD of
four independent experiments (n = 4) is indi-
cated by error bars.
In all panels the relative number of transcripts
is shown as a comparison to the level of tran-
scripts in the wild-type cells, which is given
the value 100 and indicated by a dashed line.Pax5, which had comparable AID expression to Pax5-/-/
Pax5 cells (Figure 5C). Thus, the expression of AID is def-
initely dependent on Pax5.We also analyzed the expression of transcription fac-
tors, which may have importance in B cell fate decisions.
While the expression of Ikaros, which is indispensable
Loss of Pax5 Promotes Plasmacytic Differentiation
289for the B cell development, was unaltered in the absence
of Pax5 (data not shown), the relative number of Aiolos
and EBF transcripts were diminished in the Pax5-/- cells
(Figure 5D). The reintroduction of Pax5 restored the Aio-
los expression and increased the relative number of EBF
transcripts, suggesting that Pax5 is needed for the sus-
tained expression of both Aiolos and EBF.
Discussion
Here we show that loss of Pax5 function promotes
plasma cell differentiation, as our Pax5-/- DT40 cells ex-
hibit several features of plasmacytic development. In
plasma cell differentiation, the expression of Blimp-1
and XBP-1 is upregulated with simultaneous downregu-
lation of Bcl-6 (reviewed in Calame et al., 2003), which is
exactly what we observed in ourPax5-/- cells (Figure 4A).
Moreover, XBP-1 has a major role in the induction of Ig
secretion (Reimold et al., 2001; Shaffer et al., 2004), and
IgM secretion was clearly increased in our Pax5-defi-
cient DT40 cells (Figure 4E). Plasma cells are also char-
acterized by the loss of functional B cell identity (Calame
et al., 2003), as the membrane BCR is low or absent and
increased Blimp-1 expression downregulates the tran-
scription factors, which are required for effective BCR
signaling (Shaffer et al., 2002). In line with this, our
Pax5-deficient B cells had decreased sIgM expression
(Figure 2B) and abolished BCR signaling (Figures 3A
and 3B), most likely caused by the downregulation of
several molecules involved in the BCR-signaling path-
way (Table 1). Increased Blimp-1 expression was associ-
ated with impaired growth in ourPax5-/- cells (Figures 2A
and 4A), in accordance with the observation that multiple
factors promoting proliferation and growth are inhibited
by Blimp-1 in plasmacytic cells (Lin et al., 1997; Shaffer
et al., 2002). Taken together, the impaired growth, de-
creased sIgM expression, loss of BCR signaling, in-
creased expression of Blimp-1 and XBP-1, and induction
of IgM secretion in Pax5-deficient cells are clear indica-
tions of plasmacytic differentiation. Therefore, our re-
sults demonstrate that loss of Pax5 function is sufficient
to promote plasma cell differentiation.
Our findings that Pax5 deficiency causes both down-
regulation of Bcl-6 and upregulation of Blimp-1
(Figure 4A) leads to an intriguing question about which
one of the events is the primary consequence ofPax5 tar-
geting. Enforced Blimp-1 expression has been shown to
drive plasma cell differentiation (Turner et al., 1994;
Schliephake and Schimpl, 1996; Piskurich et al., 2000).
It has also been demonstrated that Bcl-6 expression is
elevated in the germinal centers, where it prevents the
premature induction of Blimp-1 (Shaffer et al., 2000; Tu-
nyaplin et al., 2004). However, once the plasmacytic dif-
ferentiation starts, Blimp-1 is thought to directly repress
the Pax5 expression (Lin et al., 2002) and to contribute to
the downregulation of Bcl-6 (Shaffer et al., 2002). Sup-
pression of both Pax5 and Bcl-6 is critical for the plasma
cell development, as enforced expression of either Bcl-6
or Pax5 inhibits plasmacytic differentiation (Usui et al.,
1997; Morrison et al., 1998; Reljic et al., 2000; Lin et al.,
2002), and Pax5 also represses the expression of XBP-1
(Reimold et al., 1996), which is needed for the plasma
cell formation and Ig secretion (Reimold et al., 2001;
Shaffer et al., 2004). The fact that Pax5 deficiency causesincreased Blimp-1 expression and decreased Bcl-6
expression (Figure 4A) suggests that Pax5 is needed ei-
ther to inhibit Blimp-1 expression or to sustain adequate
Bcl-6 levels. However, our results indicate that Pax5 is
not needed for the suppression of Blimp-1, as enforced
Bcl-6 expression can downregulate Blimp-1 in the
Pax5-/- cells (Figure 5A). Moreover, transfected Blimp-1
can downregulate Bcl-6 in the Pax5-/-/Pax5 DT40 cells
(Figure 5B), possibly due to the double-negative regula-
tory circuit involving the Bcl-6 and Blimp-1 proteins
postulated by previous studies (Shaffer et al., 2002;
Tunyaplin et al., 2004; Fujita et al., 2004). Therefore,
Pax5 appears to be needed for the maintenance of Bcl-6,
leading to the conclusion that decrease of Bcl-6 level is
likely to constitute the primary event in the induction of
plasmacytic phenotype in the Pax5-/- cells (Figure 6).
The conditional inactivation of Pax5 in mice results in
the loss of B cell identity (Horcher et al., 2001) and simi-
larities to our Pax5-deficient B cell model including the
reduced level of surface BCR as well as the downregula-
tion of BLNK, EBF, and Igb (B29) expression. However,
the conditional inactivation of Pax5 in mice by a CD19-
cre does not lead to the increased Blimp-1 expression
nor Ig secretion (Horcher et al., 2001) observed in our
model system. This discrepancy may be related to the
differences in B cell development pathways between
the mouse and avian species. However, we believe that
a more likely explanation could be a consequence of
the c-myc overexpression in DT40 cells (Neiman et al.,
2001). c-myc is a key regulator of cell proliferation ex-
pressed in strongly dividing but not in resting quiescent
cells. Moreover, proliferation has an essential role in the
B cell activation and terminal differentiation where c-myc
is downregulated by Blimp-1 (Lin et al., 1997). Given that
enforced Blimp-1 expression has been reported to in-
duce apoptosis in the immature or only partially acti-
vated B cells (Messika et al., 1998) and that our results
reveal a spontaneous Blimp-1 expression without acti-
vation or proliferation in thePax5-/- DT40 cells, it remains
possible that in vivo Pax5-deficient mature B cells die
through apoptosis as a result of the Blimp-1 activation
and the consequent c-myc downregulation. Further-
more, conditional gene targeting of Pax5 via the CD19-
cre (Horcher et al., 2001) inactivates Pax5 already at an
early stage of B cell development and may therefore re-
sult in the reversion of the B cell commitment rather
than terminal differentiation, as suggested by studies
with conditionally Pax5-inactivated pro-B cells (Mikkola
et al., 2002). However, our findings in Pax5-/- DT40 cells
strongly indicate that Pax5 is needed to inhibit plasma
cell differentiation at later stages of B cell development.
In line with our results are findings that low Pax5 expres-
sion in B cells from multiple myeloma patients is associ-
ated with increased Blimp-1 expression (Borson et al.,
2002).
Pax5 was suspected to positively regulate AID expres-
sion, as it is known to bind to the AID promoter and en-
forced expression of Pax5 can induce AID expression
(Gonda et al., 2003). Our results unequivocally show
that AID expression is dependent on Pax5 function, con-
sistent with the observation that the expression of AID is
inhibited during plasmacytic differentiation. Introduction
of Blimp-1 expression into B cells has been shown to
promote downregulation of AID (Shaffer et al., 2002).
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in the Pax5-/-/Pax5 cells did not inhibit the expression of
AID (Figure 5C) indicate that Blimp-1 expression leads to
the downregulation of AID during plasma cell differentia-
tion via suppression of Pax5 expression rather than by
inhibiting AID directly. Thus, Pax5 likely contributes to
the regulation of SHM, CSR, and Ig gene conversion by
maintaining AID expression. In accordance, mice carry-
ing conditionally inactivated Pax5 alleles are character-
ized by reduced IgG class switching (Horcher et al.,
2001), which could be due to diminished AID expression.
Our data show that Pax5 inhibits the plasmacytic de-
velopment, because the loss of Pax5 function is suffi-
cient to promote the Ig secretion and plasma cell differ-
entiation. We suggest that the biological significance of
Pax5 expression in mature B cells is to first allow suffi-
cient clonal expansion accompanied by AID-mediated
CSR and Ig gene diversification. Once B cells with high
affinity for antigen are selected from this pool, Pax5 is
downregulated and promotes their terminal differentia-
tion into plasma cells. Recently, Pax3 was shown to
function in melanocyte differentiation as a single factor
responsible for cell fate determination and prevention
of terminal differentiation (Lang et al., 2005). Based on
our results, we propose that Pax5 has similar function
in lymphocyte development promoting B cell commit-
ment and inhibiting plasma cell differentiation. Thus,
fate determination coupled to inhibition of terminal dif-
ferentiation may be a general aspect of the Pax family
of transcriptional regulators.
Experimental Procedures
Cells and Antibodies
Wild-type andPax5mutant DT40 cells were maintained in RPMI 1640
supplemented with 10% FCS, 1% chicken serum, 50 mM b-mercap-
toethanol, 2 mM L-glutamine, penicillin, and streptomycin. Cells
were cultured at 40ºC with 5% CO2. Anti-chB6 mAb (L22) was de-
scribed previously (Pink and Rijnbeek, 1983). Anti-Pax5 mAb (A-11)
and anti-pTyr mAb (PY99) were purchased from Santa Cruz Biotech-
nology. Anti-chicken IgM mAbs (M4 and M1) and anti-chicken l light
Figure 6. A Schematic Diagram of Regulatory Network Controlling
Plasma Cell Differentiation
Our results suggest the diminishing of Bcl-6 as a primary event in the
development of plasmacytic phenotype in Pax5-deficient DT40
cells, since Pax5 is not essential to the inhibition of Blimp-1. Thus,
Pax5 is more likely needed to maintain Bcl-6 level (dashed arrow)
at later stages of B cell development. The solid lines indicate the
previously known inhibitory signals of this regulatory network.chain mAb (L1) were purchased from Southern Biotechnology Asso-
ciates Inc.
Targeting Vectors and Generation of the Pax5-Deficient
DT40 B Cell Line
In the gene-targeting constructPax5-neo, the selection cassette was
flanked by 2.0 and 2.5 kb of the chickenPax5sequence in the 50 and 30
sides, respectively (Figure 1A). The 50 flanking arm was obtained by
PCR from genomic DNA of DT40 cells by means of the primers 2f
50-GTGAACCAGCTGGGGGGCGTTTTTGTGAAT-30 and 3Lr 50-TTTA
GATCTGATCATCCAATCACTCCAGGCTAAATGCTCC-30. The3Lrpri-
mer addedBglII andBclI sites to the genomic PCR-product. An inter-
nal BamHI site within the Pax5 intron 2 was used together with the
BglII site (created by 3Lr) to clone the fragment into pUC18 vector.
The 30 flanking arm was obtained by genomic PCR by using primers
3Rf 50-ATTGCAGAGTACAAACGCCAAAATCCCACCA-30 and 4Rr 50-
TTTGGATCCGGCTGCTGCACCTTTGTCCGTATGAT-30. The 4Rr pri-
mer introduced a BamHI site, which was used for cloning together
with the internal BclI site within the Pax5 intron 3. The 30 flanking
arm was cloned the into theBclI site (created by 3Lr) of the 50 flanking
arm that had been cloned into pUC18 vector. The neomycin resis-
tance marker was cloned into the BclI site between the two flanking
Pax5 sequences.
In the Pax5-bsr construct, the selection cassette was flanked by
3.0 and 4.0 kb of the Pax5 sequence on the 50 and 30 sides, respec-
tively (Figure 1A). The 50 arm of the Pax5-bsr was obtained by geno-
mic PCR with primers b2Lf 50-CCGCGTCGACCACGGTACCGTCAG
CTAAATACTCGGCA-30and b3Lr 50-TGGTGTCGACCCTCCAATCAC
TCCAGGCTAAATGCTC-30, both creating SalI sites, which were
used in cloning of the PCR product into MCS I of the pLoxBsr vector
(Arakawa et al., 2001). The 30 flanking arm of the Pax5-bsr was ob-
tained by genomic PCR with primers b3Rf 50-AAAATTGCAGAGTACT
AGTGCCAAAATCCCACCA-30 and b4Rr 50-TTGGGCGGCCGCTGCA
CCTTTGTCCGTATGAT-30. The b3Rf created a SpeI and the b4Rr
a NotI site, which were used to clone the 30 arm into MCS II of the
pLoxBsr vector.
The Pax5-neo and Pax5-bsr were linearized by BamHI and Acc65I
digestion, respectively, and introduced into DT40 cells by electropo-
ration at 710 V, 25 mF. Stable transfectant clones were selected in the
presence of 2 mg/ml G418 (Pax5-neo transfectants) or 50 mg/ml
blasticidin S (Pax5-bsr transfectants). Pax5-targeted clones were
identified based on two genomic PCR reactions (Figure 1B), in which
the Pax5-specific primer 2f was used with the selection cassette-
specific primer neo-f 50-GCGCATCGCCTTCTATCGCCTTCTTGA
CGAG-30 or bsr-f 50-CGATTGAAGAACTCATTCCACTCAAATATAC
CC-30. The obtained PCR-products were hybridized with the Pax5-
specific probe 2p 50-GTCAGCCACGGCTGCGTCAGCAAAATACT-30.
RT-PCR Analysis
Pax5 expression of wild-type DT40, Pax5+/-, and Pax5-/- clones was
analyzed by RT-PCR. The cDNA from 1 3 105 cell equivalent, which
was prepared as indicated in Nera et al. (2006), was amplified with
primers Pax5-f 50-GTCAGCCACGGCTGCGTCAGCAAAATAC-30 and
Pax5-r 50-GGCTGCTGCACCTTTGTCCGTATGAT-30. A PCR reaction
with the chicken b-actin-specific primers b1-f 50-GTGCTGTGTTC
CCATCTATCGT-30 and b1-r 50-TGGACAATGGAGGGTCCGGATT-30
was used as a positive control. Southern hybridization was per-
formed with the Pax5-specific primer Pax5-p 50-ATTAAGCCTGGAG
TGATTGGAGGATCAA-30.
Expression Vectors and Transfections
The coding sequence of chicken Pax5, Bcl-6, and Blimp-1 was ampli-
fied from DT40 cDNA with the primers Px5-Hf 50-TATAAGCTTCGCA
ATGGATTTGGAGAAGATGTA-30 and Px5-Br 50-TATAGATCTGCTTT
GGGTCCGAGGTCAGTG-30 (for Pax-5), Bc6-Hf 50-AAAAAGCTTATG
GCCTCACCGGCAGACAGCTGCA-30 and Bc6-Nr 50-AAAGCTAGC
TCAGCAAGCCTTGGGGAGCTCCGGA-30 (for Bcl-6), and B1-Nhf
50-AAAGCTAGCATGAAAATGGACATGGAGGATGCT-30 and B1-Ncr
50-AAACCATGGTTAAGGGTCCATTGGTTCAACTGT-30 (for Blimp-1).
PCR products were cloned into the pExpress vector (Arakawa
et al., 2001) and the insert was sequenced. The expression cassettes
containing the cloned PCR products between the chicken b-actin
promoter and the SV40 poly-A sequence were excised from pEx-
press as SpeI cassettes, which were subsequently cloned into
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291pLoxPuro (Pax5 and Bcl-6) or pLoxHisD (Blimp-1) vectors (Arakawa
et al., 2001). The vectors were linearized and transfected to the
Pax5-/- (Pax5 and Bcl-6), wild-type, or Pax5-/-/Pax5 (Blimp-1) cells
at 710 V, 25 mF. Stable transfectants were selected in the presence
of 0.5 mg/ml puromycin (Pax5 and Bcl-6) or 1 mg/ml histidinol
(Blimp-1), and the expression of transfected gene was verified by im-
munoblots (Pax5) or RT-PCR (Bcl-6 and Blimp-1).
Immunoprecipitation and Western Blot Analysis
Lysates from 5 3 106 wild-type, Pax5+/-, Pax5-/-, and Pax5-/-/Pax5
cells were prepared as described previously (Nera et al., 2006) and
sequentially incubated with anti-Pax5 mAb (A-11) and protein A-aga-
rose at 4ºC overnight. The immunoprecipitates were washed four
times with the lysis buffer, and the samples were denatured at 75ºC
for 10 min in the SDS sample buffer.
In Western blot analysis, whole-cell lysates or immunoprecipitates
were separated by 4%–12% SDS-PAGE, transferred onto nitrocellu-
lose membranes, and detected by appropriate antibodies and the
enhanced chemiluminescence (ECL) system (Amersham Pharmacia
Biotech). Phosphotyrosine immunoblots for whole-cell lysates (1 3
106 cells/sample) were performed as described previously (Nera
et al., 2006).
Analysis of Cellular Growth
Wild-type, Pax5-/-, and Pax5-/-/Pax5 cell cultures were diluted to 104
cells/ml and samples were harvested at 24 hr intervals. The cell den-
sities were analyzed by flow cytometer using TruCOUNT tubes
(Becton Dickinson) according to the manufacturer’s instructions.
Calcium Measurements
Cells (106) were suspended in buffered solution containing 20 mM
HEPES, 5 mM glucose, 1 mM CaCl2, 0.25 g/l BSA, and 0.25 mM
sulfinpyrazone (Sigma) in PBS (pH 7.4) and were loaded with 3 mM
Fluo-3 AM (Molecular Probes) for 45 min at room temperature. Fol-
lowing the loading period, cells were washed three times and incu-
bated an additional 30 min to ensure the complete cleavage of
acetoxymethyl group from Fluo-3. Cells were washed twice, and
continuous monitoring of fluorescence from cell suspension (1 3
106/ml) was performed at 37ºC using a FacsCalibur flow cytometer
at the excitation wavelength of 488 nm and an emission wavelength
of 530 nm. Cells were stimulated with 4 mg/ml of M4 mAb. The aver-
age signal curve was measured by calculating the average of the fluo-
rescence value of the events at every time point.
BursaEST Array Analysis
The BursaEST array (ArrayExpress accession: A-MEXP-155, at
http://www.ebi.ac.uk/arrayexpress) contains 14,592 clones on a ny-
lon filter macroarray. The mRNA was isolated from wild-type DT40
and Pax5-/- cells, hybridized, and visualized with a phosphoimage-
reader (Fuji). A reasonable false discovery rate was chosen (about
5%) for the Significance Analysis of Microarrays (SAM) method to
define differential expression. Detailed methods and data are avail-
able at the ArrayExpress (EBI, Hinxton, UK) under the accession
E-MEXP-270 and in the Supplemental Data available with this article
online.
Quantitative Real-Time PCR
Messenger RNA was isolated from cell lines by the mRNA Isolation
Kit (Roche) and used as a template to create cDNA by the 1st Strand
cDNA Synthesis Kit for RT-PCR (AMV) (Roche). The quantitative real-
time PCR analysis was made using LightCycler equipment (Roche)
and the SYBR Green detection method. The LightCycler analysis
was made using LightCycler FastStart DNA Master SYBR Green I
kit (Roche) according to manufacturers’ instructions. 2 ml of serial
template dilutions were used. The Mg2+ concentration and PCR con-
ditions were optimized for each primer pair. Melting curve detection
was run after each analysis. GAPDH, b-actin, and elongation factor
1 (EF-1) were used to normalize the cDNA concentration. Primer
sequences are provided in the Supplemental Data.
ELISPOT Assay
The number of immunoglobulin secreting cells (ISC) was enumerated
by the enzyme-linked immunospot (ELISPOT) assay. Microtiter
plates were coated with antibody to chicken IgM (M1). Nonspecificbinding sites were blocked with 1% bovine serum albumin in PBS.
Cell suspensions were incubated in the wells for 3 hr. A biotin-labeled
anti-chicken IgL antibody (L1) was added and the plates were incu-
bated overnight at room temperature. Streptavidin-conjugated alka-
line phosphatase (Prozyme) were added and incubated for 2 hr in
37ºC. The substrate was added in hot 3% agarose, and ISC were enu-
merated by counting the spots in the wells under a light microscope.
Pulse-Chase Metabolic Labeling and IgM Precipitation
Wild-type, Pax5-/-, and Pax5-/-/Pax5 cells (4 3 107 of each) were
washed twice with PBS at room temperature. Each cell sample
was suspended to 1 ml of the methionine and cysteine-free DMEM
medium (GIBCO) supplemented with 10% dialyzed FCS and was
incubated 30 min at 40ºC. Next, 200 mCi/ml of the Redivue PRO-
MIX L-[35S] in vitro cell labeling mix (Amersham Biosciences) was
added and the cells were incubated for 15 min at 40ºC. Following
this, 4 ml of normal DMEM medium (GIBCO) containing 10% FCS
and an excess (5 mM) of L-cysteine (Sigma) and L-methionine
(Sigma) was added, and each sample was divided into five indepen-
dent 1 ml sample cultures (each containing 8 3 106 cells/ml), which
were incubated for the indicated chase times (0, 30 min, 1 hr, 2 hr,
and 4 hr). After incubation, the carefully cleared supernatants from
the samples were subjected to the IgM immunoprecipitation.
For immunoprecipitation, 50 mg of anti-IgM mAb (M1) were conju-
gated to 500 ml of protein A/G-PLUS-agarose reagent (Santa Cruz
Biotechnology) for 12 hr at 4ºC in 1 ml of lysis buffer (13 PBS, 1%
Nonidet P-40, 0.5% sodiumdeoxycholate, 1% SDS, 1 mM EDTA, 2
mM phenylmethylsulfonylfluoride, 1 mM Na3VO4, and 13 protease
inhibitor ‘‘cocktail’’ [Roche]) and then saturated for 2 hr in PBS con-
taining 5% BSA. After two washes in lysis buffer, the conjugated
M1 antibodies were suspended to 500 ml of the lysis buffer. 20 ml of
this conjugated M1 suspension was added to each cleared superna-
tant sample in immunoprecipitation and incubated for 12 hr at 4ºC.
The immunoprecipitates were washed four times with the lysis
buffer, and the samples were denatured at 75ºC for 10 min in SDS
sample buffer and separated by 4%–12% SDS-PAGE. The radioac-
tive gels were fixed in 15% methanol, 7.5% acetic acid and treated
with Enlightning autoradiography enhancer (PerkinElmer) before
drying and exposure on autoradiographic film.
Supplemental Data
Supplemental Experimental Procedures can be found with this
article online at http://www.immunity.com/cgi/content/full/24/3/
283/DC1/.
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